Oppenheimer analyst Hartaj Singh maintained a Buy rating on Biomea Fusion (BMEA – Research Report) today and set a price target of $70.00. The company’s shares closed yesterday at $18.60.
Singh covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Regeneron, and Biomea Fusion. According to TipRanks, Singh has an average return of 14.8% and a 47.14% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Biomea Fusion with a $58.50 average price target, a 214.52% upside from current levels. In a report released today, Truist Financial also initiated coverage with a Buy rating on the stock with a $55.00 price target.
See today’s best-performing stocks on TipRanks >>
BMEA market cap is currently $659.5M and has a P/E ratio of -5.56.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biomea Fusion (BMEA) Company Description:
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companies lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Read More on BMEA:
- Biomea Fusion announces anticipated 2024 corporate milestones
- Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
- Biomea Fusion doses first patient with type 1 diabetes in COVALENT-112 trial
- Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
- Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
